CXCR2 and neoplasm: Crucially, they can be genetically engineered at early developmental stages to integrate synthetic enhancements such as chemokine receptors (e.g., CXCR2 or CCR7), checkpoint resistance modules, or cytokine support systems, thus ensuring improved trafficking, survival, and cytotoxic function in the immunosuppressive tumor microenvironment [24].